A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
As many as half of obsessive-compulsive disorder (OCD) patients treated with an adequate trial of serotonin reuptake inhibitors (SRIs) fail to fully respond to treatment and continue to exhibit significant symptoms. Many studies have assessed the effectiveness of antipsychotic augmentation in SRI-refractory OCD. In this systematic review, we evaluate the efficacy of antipsychotic augmentation in treatment-refractory OCD. The electronic databases of PubMed, PsychINFO (1967-2005), Embase (1974-2000) and the Cochrane Central Register of Controlled Trials (CENTRAL, as of 2005, Issue 3) were searched for relevant double-blind trials using keywords 'antipsychotic agents' or 'neuroleptics' and 'obsessive-compulsive disorder'. Search results and analysis were limited to double-blind, randomized control trials involving the adult population. The proportion of subjects designated as treatment responders was defined by a greater than 35% reduction in Yale Brown Obsessive-Compulsive Scale (Y-BOCS) rating during the course of augmentation therapy. Nine studies involving 278 participants were included in the analysis. The meta-analysis of these studies demonstrated a significant absolute risk difference (ARD) in favor of antipsychotic augmentation of 0.22 (95% confidence interval (CI): 0.13, 0.31). The subgroup of OCD patients with comorbid tics have a particularly beneficial response to this intervention, ARD=0.43 (95% CI: 0.19, 0.68). There was also evidence suggesting OCD patients should be treated with at least 3 months of maximal-tolerated therapy of an SRI before initiating antipsychotic augmentation owing to the high rate of treatment response to continued SRI monotherapy (25.6%). Antipsychotic augmentation in SRI-refractory OCD is indicated in patients who have been treated for at least 3 months of maximal-tolerated therapy of an SRI. Unfortunately, only one-third of treatment-refractory OCD patients show a meaningful treatment response to antipsychotic augmentation. There is sufficient evidence in the published literature, demonstrating the efficacy of haloperidol and risperidone, and evidence regarding the efficacy of quetiapine and olanzapine is inconclusive. Patients with comorbid tics are likely to have a differential benefit to antipsychotic augmentation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“there are some case reports that methylphenidate can worsen OCD symptoms [174] and for some patients antipsychotic medications that reduce dopamine levels are effective [175] (Table 3).”
From Toward a neurocircuit-based taxonomy to guide treatment of obsessive-compulsive disorder (2021) · cites this paper as [175]
In the citing paper
“A meta-analysis of the adult literature examining the use of antipsychotic augmentation in the treatment of OCD showed that the NNT for OCD and tics was 2.3 compared to 5.9 for those with OCD alone.”
From Practice Parameter for the Assessment and Treatment of Children and Adolescents With Tic Disorders (2013) · cites this paper as [139]
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
(1996) · Cited by 6,884
Charbonneau, D. H. (2005) · Europe PMC (PubMed Central) · Cited by 2,041
The Epidemiology of Obsessive-Compulsive Disorder in Five US Communities
Karno, M. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800360042006 · Cited by 1,351
A 40-Year Follow-up of Patients With Obsessive-compulsive Disorder
Skoog, G., & Skoog, I. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.2.121 · Cited by 632
McDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571
McDougle, C. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950040046006 · Cited by 570
The International Journal of Neuropsychopharmacology
Lerer, B., Frazer, A., Stahl, S., Farde, L., & Lesch, P. (1998) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145798009018 · Cited by 501
The Epidemiology and Differential Diagnosis of Obsessive-Compulsive Disorder
Rasmussen, S. A., & Eisen, J. L. (1992) · Zwangsstörungen / Obsessive-Compulsive Disorders · doi:10.1007/978-3-642-77608-3_1 · Cited by 493
Research works printed but not linked: 2
- Muller C . Vorlaufige Mitteilung zur langen Katamnese der Zwangskranken. Nervenartz 1953; 24: 112–115.
- Rennie TAC . Prognosis in the Psychoneurosis: Benign and Malignant Developments, Current Problems in Psychiatric Diagnosis. New York: Grune & Stratton Inc, 1953.
Cited by
Psychiatric Comorbidities and Schizophrenia
Buckley, P. F., Miller, B. J., Lehrer, D. S., & Castle, D. J. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn135 · Cited by 1,121
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“response rates [816,817].”
Neurocognitive endophenotypes of impulsivity and compulsivity: Towards dimensional psychiatry
Robbins, T. W., Gillan, C. M., Smith, D. G., de Wit, S., & Ersche, K. D. (2012) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2011.11.009 · Cited by 1,003
Abramowitz, J. S., Taylor, S., & McKay, D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60240-3 · Cited by 1,002
Stein, D. J., Costa, D. L. C., Lochner, C., Miguel, E. C., Reddy, Y. C. J., Shavitt, R. G., van den Heuvel, O. A., & Simpson, H. B. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0102-3 · Cited by 895
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Probing compulsive and impulsive behaviors, from animal models to endophenotypes: A narrative review
Fineberg, N. A., Potenza, M. N., Chamberlain, S. R., Berlin, H. A., Menzies, L., Bechara, A., Sahakian, B. J., Robbins, T. W., Bullmore, E. T., & Hollander, E. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.185 · Cited by 654
“Antipsychotics represent first-line treatment for Tourette’s syndrome, and it is, therefore, interesting that their combination with SSRIs shows greater efficacy in ticrelated OCD (Bloch et al, 2006).”
BackgroundClinical course of Tourette syndrome
Bloch, M. H., & Leckman, J. F. (2009) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2009.09.002 · Cited by 513
“A meta-analysis of antipsychotic augmentation trials for treatment refractory OCD suggests that OCD patients with comorbid tics may have an improved response to this intervention [38].”
Self-citationGeller, D. A., & March, J. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2011.09.019 · Cited by 514
“High-quality randomized controlled trials using atypicals have been performed in adults with OCD and are summarized in a comprehensive meta-analysis by Bloch et al., 63 but no controlled data exist in children and only case reports and open trials have been reported.”
BackgroundObsessive-Compulsive Disorder: Advances in Diagnosis and Treatment
Hirschtritt, M. E., Bloch, M. H., & Mathews, C. A. (2017) · JAMA · doi:10.1001/jama.2017.2200 · Cited by 493
“a Severity of OCD as determined by Obsessive-Compulsive Inventory, Short Version (OCI-R) scores: mild (scores of 15-19), moderate (20-34), and severe ( 35).”
MethodSelf-citationthe ESSTS Guidelines Group, Roessner, V., Plessen, K. J., Rothenberger, A., Ludolph, A. G., Rizzo, R., Skov, L., Strand, G., Stern, J. S., Termine, C., et al. (2011) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-011-0163-7 · Cited by 461
“Coadministration of an antipsychotic agent may be helpful [20, 56].”
BackgroundPittenger, C., Bloch, M. H., & Williams, K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.006 · Cited by 426
“However, therapies aimed at modulating serotonin and dopamine prove inadequate in many cases of OCD; ~25% of patients get little benefit from available treatment strategies, and many of those who are classified as ‘responders’ continue to have significant symptoms and markedly reduced quality of life (Koran et al., 19…”
BackgroundSelf-citationLeckman, J. F., Denys, D., Simpson, H. B., Mataix-Cols, D., Hollander, E., Saxena, S., Miguel, E. C., Rauch, S. L., Goodman, W. K., Phillips, K. A., et al. (2010) · Depression and Anxiety · doi:10.1002/da.20669 · Cited by 411
“However, these tic-related cases may be less likely to respond to SSRIs alone and more likely to benefit from SSRI augmentation with a neuroleptic.([77,78,80]) Although the literature on augmentation trials is about current tics, the value of classifying by lifetime tics is that it encourages a developmental perspecti…”
BackgroundSelf-citationRandomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.150 · Cited by 386
“Adding antipsychotics to SRIs helps a subset of patients (Bloch et al , 2006) but risks burdensome side effects.”
Should an obsessive-compulsive spectrum grouping of disorders be included in DSM-V?
Phillips, K. A., Stein, D. J., Rauch, S. L., Hollander, E., Fallon, B. A., Barsky, A., Fineberg, N., Mataix-Cols, D., Ferrão, Y. A., Saxena, S., et al. (2010) · Depression and Anxiety · doi:10.1002/da.20705 · Cited by 347
Self-citationGoal-directed learning and obsessive-compulsive disorder
Gillan, C. M., & Robbins, T. W. (2014) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2013.0475 · Cited by 348
Simpson, H. B., Foa, E. B., Liebowitz, M. R., Ledley, D. R., Huppert, J. D., Cahill, S., Vermes, D., Schmidt, A. B., Hembree, E., Franklin, M., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07091440 · Cited by 316
A direct GABAergic output from the basal ganglia to frontal cortex
Saunders, A., Oldenburg, I. A., Berezovskii, V. K., Johnson, C. A., Kingery, N. D., Elliott, H. L., Xie, T., Gerfen, C. R., & Sabatini, B. L. (2015) · Nature · doi:10.1038/nature14179 · Cited by 293
Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder
Goodman, W. K., Storch, E. A., & Sheth, S. A. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20111601 · Cited by 250
The neurobiology of repetitive behavior: …and men
Langen, M., Durston, S., Kas, M. J. H., van Engeland, H., & Staal, W. G. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.02.005 · Cited by 263
“…such as olanzapine, quetiapine, ziprasidone and risperidone are often prescribed in severe cases of OCD and are considered a useful augmentation if SSRI treatment is not successful, putatively suggesting that in OCD dopamine–serotonin interactions may also be relevant (Bloch et al., 2006).”
BackgroundPractice Parameter for the Assessment and Treatment of Children and Adolescents With Tic Disorders
Murphy, T. K., Lewin, A. B., Storch, E. A., & Stock, S. (2013) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.09.015 · Cited by 276
“9 for those with OCD alone.(139) One open-label study reported improvement in OCD severity when aripiprazole was used to treat tic disorders.”
BackgroundThe role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder
Wu, K., Hanna, G. L., Rosenberg, D. R., & Arnold, P. D. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.10.007 · Cited by 264
“…are also used to augment treatment by serotonin reuptake inhibitors (SRIs) in treatment-refactory patients with OCD, yet they only work in approximately a third of cases and are associated with significant adverse effects (particularly metabolic side effects and weight gain) (Bloch et al., 2006).”
Clinical assessment of Tourette syndrome and tic disorders
Cohen, S. C., Leckman, J. F., & Bloch, M. H. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.11.013 · Cited by 233
Self-citationMultiple pathways to functional impairment in obsessive-compulsive disorder
Markarian, Y., Larson, M. J., Aldea, M. A., Baldwin, S. A., Good, D., Berkeljon, A., Murphy, T. K., Storch, E. A., & McKay, D. (2010) · Clinical Psychology Review · doi:10.1016/j.cpr.2009.09.005 · Cited by 252
“and incomplete responders (Bloch et al., 2006).”
Toward a neurocircuit-based taxonomy to guide treatment of obsessive-compulsive disorder
Shephard, E., Stern, E. R., van den Heuvel, O. A., Costa, D. L. C., Batistuzzo, M. C., Godoy, P. B. G., Lopes, A. C., Brunoni, A. R., Hoexter, M. Q., Shavitt, R. G., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-01007-8 · Cited by 250
Simpson, H. B., Foa, E. B., Liebowitz, M. R., Huppert, J. D., Cahill, S., Maher, M. J., McLean, C. P., Bender, J., Marcus, S. M., Williams, M. T., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1932 · Cited by 248
“Forexample, McDougle et al6 treated patients for 8 weeks with an SRI and then randomized only those who met all of the following criteria: (1) less than 35% Y-BOCS score decrease or Y-BOCS score more than 16; (2) no more than minimal improvement; and (3) consensus of 3 clinicians that the patient was unimproved.”
Tourette Syndrome and Tic Disorders: A Decade of Progress
SWAIN, J. E., SCAHILL, L., LOMBROSO, P. J., KING, R. A., & LECKMAN, J. F. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318068fbcc · Cited by 238
“Unauthorized reproduction of this article is prohibited. poorer performance with the dominant hand on the Purdue Pegboard test during childhood is associated with worse adulthood tic severity (Bloch et al., 2006b).”
BackgroundInfluentialSelf-citationPsychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD)
Del Casale, A., Sorice, S., Padovano, A., Simmaco, M., Ferracuti, S., Lamis, D. A., Rapinesi, C., Sani, G., Girardi, P., Kotzalidis, G. D., et al. (2019) · Current Neuropharmacology · doi:10.2174/1570159x16666180813155017 · Cited by 223
Pharmacological Treatment of Obsessive-Compulsive Disorder
Pittenger, C., & Bloch, M. H. (2014) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2014.05.006 · Cited by 222
“A recent metaanalysis of 9 double-blind, placebo controlled trials of augmentation with typical or atypical antipsychotics demonstrated their efficacy compared to placebo [22, 23].”
BackgroundSelf-citationRoessner, V., Eichele, H., Stern, J. S., Skov, L., Rizzo, R., Debes, N. M., Nagy, P., Cavanna, A. E., Termine, C., Ganos, C., et al. (2022) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-021-01899-z · Cited by 197
“In treatment resistant OCD in the context of TS, antipsychotic augmentation of treatment with SSRI using aripiprazole and risperidone may be considered [180]; the subgroup of patients with OCD and co-existing tics had a particularly beneficial response to treatment with antipsychotic augmentation in a meta-analysis [1…”
BackgroundInfluentialInflammation in the Neurocircuitry of Obsessive-Compulsive Disorder
Attwells, S., Setiawan, E., Wilson, A. A., Rusjan, P. M., Mizrahi, R., Miler, L., Xu, C., Richter, M. A., Kahn, A., Kish, S. J., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1567 · Cited by 204
Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000740 · Cited by 211
Fineberg, N. A., Apergis-Schoute, A. M., Vaghi, M. M., Banca, P., Gillan, C. M., Voon, V., Chamberlain, S. R., Cinosi, E., Reid, J., Shahper, S., et al. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx088 · Cited by 183
“Additionally, tic-related OCD shows a more favorable response to adjunctive treatment with dopamine antagonist drugs (Bloch et al., 2006).”
Heyman, I. (2006) · BMJ · doi:10.1136/bmj.333.7565.424 · Cited by 166
European clinical guidelines for Tourette Syndrome and other tic disorders
Roessner, V., Rothenberger, A., Rickards, H., & Hoekstra, P. J. (2011) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-011-0165-5 · Cited by 171
Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder
Bloch, M. H., Wasylink, S., Landeros-Weisenberger, A., Panza, K. E., Billingslea, E., Leckman, J. F., Krystal, J. H., Bhagwagar, Z., Sanacora, G., & Pittenger, C. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.028 · Cited by 162
“Antipsychotic augmentation is the only pharmacoogical strategy for treatment-refractory OCD with demonstrated fficacy in multiple double-blind trials (2); but antipsychotic augentation only benefits approximately 1 in 3 of these patients (2).”
Self-citationFineberg, N. A., Hollander, E., Pallanti, S., Walitza, S., Grünblatt, E., Dell’Osso, B. M., Albert, U., Geller, D. A., Brakoulias, V., Janardhan Reddy, Y. C., et al. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000314 · Cited by 161
“The presence of tic symptomatology represents another clinically relevant diagnostic specifier in the DSM-5, as tic may predict a more favourable response to dopamine antagonist agents (Bloch et al., 2006).”
BackgroundObsessive–compulsive disorder comorbidity: Clinical assessment and therapeutic implications
Pallanti, S., Grassi, G., Sarrecchia, E. D., Cantisani, A., & Pellegrini, M. (2011) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2011.00070 · Cited by 158
“Roughly one-third to one-half of children with Tourette syndrome (TS) or chronic tic disorder will experience comorbid OCD throughout their lifetime (Bloch et al., 2006a).”
BackgroundA trans-diagnostic perspective on obsessive-compulsive disorder
Gillan, C. M., Fineberg, N. A., & Robbins, T. W. (2017) · Psychological Medicine · doi:10.1017/s0033291716002786 · Cited by 158
“In the case of selective serotonin re-uptake inhibitor (SSRI)-resistant OCD, a preferential effect for treatment with dopamine antagonists was seen for those with co-morbid tics (Bloch et al. 2006).”
InfluentialTranscranial direct current stimulation in psychiatric disorders
Tortella, G. (2015) · World Journal of Psychiatry · doi:10.5498/wjp.v5.i1.88 · Cited by 154
Ghaleiha, A., Entezari, N., Modabbernia, A., Najand, B., Askari, N., Tabrizi, M., Ashrafi, M., Hajiaghaee, R., & Akhondzadeh, S. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.09.015 · Cited by 152
Pharmacotherapy of anxiety disorders: A critical review
Koen, N., & Stein, D. J. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/nkoen · Cited by 151
Fineberg, N. A., Reghunandanan, S., Simpson, H. B., Phillips, K. A., Richter, M. A., Matthews, K., Stein, D. J., Sareen, J., Brown, A., & Sookman, D. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2014.12.003 · Cited by 150
“However, this strategy is effective in only roughly one third of cases (Bloch et al., 2006).”
BackgroundYu, D., Mathews, C. A., Scharf, J. M., Neale, B. M., Davis, L. K., Gamazon, E. R., Derks, E. M., Evans, P., Edlund, C. K., Crane, J., et al. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13101306 · Cited by 148
Self-citationDrug treatment of obsessive-compulsive disorder
Kellner, M. (2010) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2010.12.2/mkellner · Cited by 145
Advantages and disadvantages of combination treatment with antipsychotics
Goodwin, G. M., Fleischhacker, W., Arango, C., Baumann, P., Davidson, M., Binder, M. D., Falkai, P., Kapur, S., Leucht, S., Licht, R. W., et al. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.04.003 · Cited by 164
“The sub-group of OCDwith tic may have a relatively higher responsiveness than thosewithout (Bloch et al., 2006).”
BackgroundGrant, J. E. (2014) · New England Journal of Medicine · doi:10.1056/nejmcp1402176 · Cited by 148
Neurobiology of Obsessive-Compulsive Disorder:Serotonin and Beyond
Westenberg, H. G. M., Fineberg, N. A., & Denys, D. (2007) · CNS Spectrums · doi:10.1017/s1092852900002479 · Cited by 148
“Mirtazapine, although not effective by itself, has shown to hasten the effect of paroxetine(72) and several studies have shown that atypical antipsychotics augment the effects of SSRIs in refractory OCD patients.(73) Moreover, mCPP, a nonselective 5-HT2 receptor agonist is either not effective or causes a worsening of…”
BackgroundResultDold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv047 · Cited by 134
“Furthermore, we could confirm previous meta-analytic findings demonstrating an efficacy of the adjunctive antipsychotic pharmacotherapy (Bloch et al., 2006; Skapinakis et al., 2007).”
ResultRepetitive Behaviours in Patients with Gilles de la Tourette Syndrome: Tics, Compulsions, or Both?
Worbe, Y., Mallet, L., Golmard, J.-L., Béhar, C., Durif, F., Jalenques, I., Damier, P., Derkinderen, P., Pollak, P., Anheim, M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012959 · Cited by 127
Dougherty, D. D., Brennan, B. P., Stewart, S. E., Wilhelm, S., Widge, A. S., & Rauch, S. L. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.0930 · Cited by 131
Predictors of early adult outcomes in pediatric-onset obsessive-compulsive disorder
Bloch, M. H., Craiglow, B. G., Landeros-Weisenberger, A., Dombrowski, P. A., Panza, K. E., Peterson, B. S., & Leckman, J. F. (2009) · Pediatrics · doi:10.1542/peds.2009-0015 · Cited by 129
Self-citationClozapine-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Critical Review
Schirmbeck, F., & Zink, M. (2012) · Current Neuropharmacology · doi:10.2174/157015912799362724 · Cited by 123
“For patients with primary OCD, exhibiting treatmentresistance to serotonergic antidepressants, favourable effects of SGAs, including those with antiserotonergic properties such as risperidone, have been reported [79-81].”
BackgroundRole of dopamine in the pathophysiology and treatment of obsessive–compulsive disorder
Koo, M.-S., Kim, E.-J., Roh, D., & Kim, C.-H. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.148 · Cited by 125
Schirmbeck, F., & Zink, M. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00099 · Cited by 118
“Furthermore, antiobsessive effects of antipsychotics have also been reported in primary OCD, including OLZ, especially in cases with treatmentresistance to serotonergic antidepressants (Bloch et al., 2006; Bandelow et al., 2008; Dold et al., 2011; Muscatello et al., 2011).”
BackgroundClinically relevant interactions between newer antidepressants and second-generation antipsychotics
Spina, E., & de León, J. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.885504 · Cited by 136
“5-HT: Serotonin receptor; a: a adrenergic receptor; H: Histamine receptor; MT: Melatonin receptors; OCD: Obsessive-compulsive disorder; RCT: Randomized clinical trial; SSRI: Selective serotonin reuptake inhibitor.”
BackgroundInfluentialMuscatello, M. R. A., Bruno, A., Pandolfo, G., Micò, U., Scimeca, G., Romeo, V. M., Santoro, V., Settineri, S., Spina, E., & Zoccali, R. A. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31820e3db6 · Cited by 122
Zuddas, A., Zanni, R., & Usala, T. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.04.001 · Cited by 131
“…double-blind randomized placebocontrolled trials have shown the efficacy of risperidone as augmentation therapy for adult SRI-refractory obsessive compulsive disorder with and without tics (see Bloch et al., 2006 for a systematic review), but similar studies are lacking in children and adolescent.”
Abramovitch, A., Dar, R., Mittelman, A., & Wilhelm, S. (2015) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000050 · Cited by 120
“, neuroleptic/antipsychotic agents) have been found to be useful for SRI augmentation among OCD patients who only partially respond to SRIs.(125) In sum, ADHD and OCD are two psychiatric syndromes that appear to lie on opposite ends of an impulsive-compulsive continuum (see Table 1).”
BackgroundTourette syndrome and obsessive–compulsive disorder
Lombroso, P. J., & Scahill, L. D. (2007) · Brain and Development · doi:10.1016/j.braindev.2007.09.001 · Cited by 126
“Additional research is necessary to determine whether autoantibodies are produced in vulnerable individuals and whether these are etiologically related to the symptoms observed in PANDAS cases.”
BackgroundPharmacological Management of Treatment-Resistant Obsessive-Compulsive Disorder
Abudy, A., Juven‐Wetzler, A., & Zohar, J. (2011) · CNS Drugs · doi:10.2165/11587860-000000000-00000 · Cited by 119
Mosley, P. E., Windels, F., Morris, J., Coyne, T., Marsh, R., Giorni, A., Mohan, A., Sachdev, P., O’Leary, E., Boschen, M., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01307-9 · Cited by 117
Children with obsessive-compulsive disorder: are they just “little adults”?
Kalra, S. K., & Swedo, S. E. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37563 · Cited by 114
Serotoninergic mechanisms in the treatment of obsessive–compulsive disorder
Goddard, A. W., Shekhar, A., Whiteman, A. F., & McDougle, C. J. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.12.009 · Cited by 112
Abramowitz, J. S., Mahaffey, B. L., & Wheaton, M. G. (2010) · The Corsini Encyclopedia of Psychology · doi:10.1002/9780470479216.corpsy0617 · Cited by 62
Bloch, M. H., Landeros‐Weisenberger, A., Sen, S., Dombrowski, P., Kelmendi, B., Coric, V., Pittenger, C., & Leckman, J. F. (2008) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30699 · Cited by 108
“OCD patients with comorbid tics have demonstrated poorer response to treatment with SRIs and improved response to antipsychotic augmentation [Leckman et al., 1994; Bloch et al., 2006; March et al., 2007].”
BackgroundSelf-citationAssessment and Management of Treatment-Refractory Obsessive-Compulsive Disorder in Children
Bloch, M. H., & Storch, E. A. (2015) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2015.01.011 · Cited by 104
Self-citationSymptom dimensions and subtypes of obsessive-compulsive disorder: a developmental perspective
Leckman, J. F., Bloch, M. H., & King, R. A. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.1/jfleckman · Cited by 106
“However, up to 40% to 60% of patients do not have a satisfactory outcome.(75,76) Nonresponse to treatment in OCD is associated with serious social disability.”
BackgroundSelf-citationFerrão, Y. A., Miguel, E., & Stein, D. J. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2008.06.008 · Cited by 107
“In OCD plus TS patients, the worst-ever OCD symptoms occurred approximately 2 years later than worst-ever tic symptoms, and the OCD symptoms were more likely to persist than tic symptoms (Bloch et al., 2006a).”
BackgroundResultPlasma cytokine abnormalities in drug-naïve, comorbidity-free obsessive-compulsive disorder.
Rao, N.-R. P., Venkatasubramanian, G., Ravi, V., Kalmady, S., Cherian, A., & Yc, J. R. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.07.009 · Cited by 94
Sayyah, M., Sayyah, M., Boostani, H., Ghaffari, S. M., & Hoseini, A. (2012) · Depression and Anxiety · doi:10.1002/da.21996 · Cited by 105
Bruno, A., Micò, U., Pandolfo, G., Mallamace, D., Abenavoli, E., Di Nardo, F., D’Arrigo, C., Spina, E., Zoccali, R. A., & Muscatello, M. R. A. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111431751 · Cited by 103
“Augmentation strategies largely consist of the use of atypical antipsychotics (Bloch et al., 2006; Fineberg et al., 2006; Gao et al., 2006; Goodwin et al., 2009), with positive evidence for risperidone, olanzapine, quetiapine, and aripiprazole (D’Amico et al., 2003; McDougle et al., 2000;…”
BackgroundSecond-generation antipsychotics for obsessive compulsive disorder
Komossa, K., Depping, A. M., Meyer, M., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008141.pub2 · Cited by 96
Dell’Osso, B., Buoli, M., Hollander, E., & Altamura, A. C. (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622970903418544 · Cited by 96
“Nonetheless, up to 40–60% of patients do not completely recover after a single SRI trial and are eligible for second-line treatments with a combination of SRIs and other compounds such as antipsychotics (both typical and atypical) (Bloch et al. 2006; Marazziti et al. 2008), proserotonergic compounds (e.”
BackgroundClinical implications of insight assessment in obsessive-compulsive disorder
Alonso, P., Menchón, J. M., Segalàs, C., Jaurrieta, N., Jiménez‐Múrcia, S., Cardoner, N., Labad, J., Real, E., Pertusa, A., & Vallejo, J. (2007) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2007.09.005 · Cited by 107
“Although to date, it has not been shown that the addition of antipsychotics to SRI improves the treatment response of poor insight patients with OCD [35], this is a pharmacologic strategy that is often used by clinicians.”
BackgroundClinical features of Tourette syndrome and tic disorders
Leckman, J. F., King, R. A., & Bloch, M. H. (2014) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2014.03.004 · Cited by 103
Self-citationTreatment-resistant OCD: Pharmacotherapies in adults
van Roessel, P. J., Grassi, G., Aboujaoude, E. N., Menchón, J. M., Van Ameringen, M., & Rodríguez, C. I. (2023) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2022.152352 · Cited by 86
Addicted to Hair Pulling? How an Alternate Model of Trichotillomania May Improve Treatment Outcome
Grant, J. E., Odlaug, B. L., & Potenza, M. N. (2007) · Harvard Review of Psychiatry · doi:10.1080/10673220701298407 · Cited by 99
Ahmari, S. E., & Rauch, S. L. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-021-01130-2 · Cited by 95
Semiz, Ü. B., İnanç, L., & Bezgin, Ç. (2013) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-013-0787-7 · Cited by 101
“lation and is the fourth most common psychiatric illness [2].”
BackgroundDeep brain stimulation for obsessive–compulsive disorder: a systematic review and meta-analysis
Kisely, S., Hall, K., Siskind, D., Frater, J., Olson, S., & Crompton, D. (2014) · Psychological Medicine · doi:10.1017/s0033291714000981 · Cited by 95
“Unfortunately, approximately 25% of patients drop out of CBT and 40–60% do not respond adequately to SSRIs or clomipramine (Bloch et al. 2006).”
BackgroundFonseka, T. M., Richter, M. A., & Müller, D. J. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0510-8 · Cited by 93
Personalized Transcranial Magnetic Stimulation in Psychiatry
Cocchi, L., & Zalesky, A. (2018) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2018.01.008 · Cited by 106
“However, existing interventions only partially offset the burden of disease, and a number of individuals remain clinically symptomatic after treatment (3,4).”
BackgroundVarigonda, A. L., Jakubovski, E., & Bloch, M. H. (2016) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2016.07.768 · Cited by 94
Self-citationMaina, G., Pessina, E., Albert, U., & Bogetto, F. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.01.001 · Cited by 101
“Recent meta-analyses of the randomized trials supported the use of antipsychotic augmentation as a promising strategy for treatment-resistant OCD patients, although pointed towards the need for more and larger trials, as differences might exist between different antipsychotics (Bloch et al., 2006; Ipser et al., 2006;…”
ResultAlbert, U., Marazziti, D., Di Salvo, G., Solia, F., Rosso, G., & Maina, G. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867325666171222163645 · Cited by 90
Animal models of obsessive–compulsive disorder: utility and limitations
Alonso, P., López‐Solà, C., Real, E., Segalàs, C., & Menchón, J. M. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s62785 · Cited by 101
“N -methyl-[7-(1-pyrrolidinyl)-1-oxaspirol[4.5]dec-8-yl]-benzeneacetamide (U69593), facilitated the development of quinpirole-induced compulsive checking, whereas treatment with the kappa agonist on its own had no behavioral effect.”
InfluentialMarble-burying behavior test as a murine model of compulsive-like behavior
Dixit, P. V., Sahu, R. A., & Mishra, D. K. (2020) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2020.106676 · Cited by 92
Conelea, C. A., Walther, M. R., Freeman, J. B., Garcia, A. M., Sapyta, J., Khanna, M., & Franklin, M. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.09.014 · Cited by 82
Zike, I. D., Xu, T., Hong, N., & Veenstra-VanderWeele, J. M. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.09.012 · Cited by 87
“On the other hand, the Cntnap2 null mouse does show decreased grooming with a non-sedating dose of risperidone, an atypical antipsychotic medication frequently used in ASD but also used as an adjunctive medication in OCD (Bloch et al., 2006).”
BackgroundPittenger, C., Kelmendi, B., Wasylink, S., Bloch, M. H., & Coric, V. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181727548 · Cited by 81
Self-citationTranslational approaches to obsessive‐compulsive disorder: from animal models to clinical treatment
Fineberg, N., Chamberlain, Sr., Hollander, E., Boulougouris, V, & Robbins, T. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01422.x · Cited by 82
Cocchi, L., Zalesky, A., Nott, Z., Whybird, G., Fitzgerald, P. B., & Breakspear, M. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.05.029 · Cited by 76
“, 2017), over 40% of patients remain clinically symptomatic and highly disabled for decades after initial treatment (Bloch et al., 2006; Pallanti and Quercioli, 2006).”
BackgroundError-related negativity and tic history in pediatric obsessive-compulsive disorder
Hanna, G. L., Carrasco, M., Harbin, S. M., Nienhuis, J. K., LaRosa, C. E., Chen, P., Fitzgerald, K. D., & Gehring, W. J. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.06.019 · Cited by 80
Pittenger, C., Bloch, M. H., Wasylink, S., Billingslea, E., Simpson, R., Jakubovski, E., Kelmendi, B., Sanacora, G., & Coric, V. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09123 · Cited by 80
Self-citationTourette syndrome and obsessive compulsive disorder: Compulsivity along the continuum
Eddy, C. M., & Cavanna, A. E. (2014) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2014.04.003 · Cited by 84
Kordon, A., Wahl, K., Koch, N., Zurowski, B., Anlauf, M., Vielhaber, K., Kahl, K. G., Broocks, A., Voderholzer, U., & Hohagen, F. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318185e735 · Cited by 78
“Reports on placebo-controlled trials of SRI augmentation using haloperidol, risperidone, olanzapine, and quetiapine support further exploration of the efficacy of this approach in treatment-resistant OCD, although negative as well as positive findings have been reported.(2) Because OCD patients typically require prolo…”
BackgroundAugmentation strategies in obsessive–compulsive disorder
Arumugham, S. S., & Reddy, J. Y. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.160 · Cited by 75
Storch, E. A., Lewin, A. B., Geffken, G. R., Morgan, J. R., & Murphy, T. K. (2010) · Behaviour Research and Therapy · doi:10.1016/j.brat.2010.09.004 · Cited by 78
Meta-analysis: Adulthood prevalence of Tourette syndrome
Levine, J. L. S., Szejko, N., & Bloch, M. H. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109675 · Cited by 85
Self-citation
Metadata
- Authors
- Bloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V, Bracken, M. B., & Leckman, J. F.
- Affiliations
- Yale University (US)
- Connecticut Mental Health Center (US)
- Corresponding author
- Bloch, M H
- Venue
- Molecular Psychiatry
- Published
- 2006-04-04
- Volume
- 11
- Issue
- 7
- Pages
- 622-632
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2100202859
- Cited by
- 635
- References
- 50
- Citations by year
- 2026: 24 · 2025: 21 · 2024: 22 · 2023: 14 · 2022: 18 · 2021: 25 · 2020: 21 · 2019: 29 · 2018: 34 · 2017: 37 · 2016: 30 · 2015: 53 · 2014: 48 · 2013: 39 · 2012: 39
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Update notices
- erratum (2006-07-26)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Tourette Association of America
- National Institutes of Health
- U.S. Public Health Service
- National Institute of Mental Health
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- obsessive-compulsive disorder, treatment-refractory OCD, antipsychotic augmentation, serotonin reuptake inhibitors, haloperidol, risperidone, quetiapine, olanzapine, treatment response, Yale-Brown Obsessive Compulsive Scale
- MeSH terms
- Quetiapine Fumarate, Olanzapine, Adult, Aged, Basal Ganglia Diseases, Benzodiazepines, Depressive Disorder, Dibenzothiazepines, Double-Blind Method, Drug Resistance, Drug Therapy, Combination, Haloperidol, Humans, Middle Aged, Obsessive-Compulsive Disorder, Patient Dropouts, Tic Disorders, Antipsychotic Agents, Comorbidity, Randomized Controlled Trials as Topic, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.